SCHEMBL1464103

SCHEMBL1464103

Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)c(C(=O)O)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 8/20 0.82
MEN1 O00255 6/20 0.68
KMT2A Q03164 6/20 0.68
ALDH1A1 P00352 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
MAPT P10636 3/20 0.63
HTT P42858 3/20 0.63
RAB9A P51151 1/20 0.63
LMNA P02545 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
ATM Q13315 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
AKR1C3 P42330 1/20 0.59
AKR1C2 P52895 1/20 0.59
KDR P35968 1/20 0.57
MPO P05164 3/20 0.56
TP53 P04637 1/20 0.56
POLB P06746 1/20 0.56
XBP1 P17861 1/20 0.56
ALOX12 P18054 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468541 0.90 GRIK1 (0.81) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL16946692 0.88 GRIK1 (0.70) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL1463509 0.88 GRIK1 (0.77) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL1462324 0.86 GRIK1 (0.82) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL1463277 0.85 GRIK1 (0.82) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL5464394 0.85 GRIK1 (0.82) GRIK1MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL1463485 0.85 AKR1C3 (0.70) GRIK1MEN1KMT2AMAPTHTT
SCHEMBL1463217 0.85 GRIK1 (1.00) GRIK1MEN1KMT2AMAPTHTT
SCHEMBL10192109 0.83 KMT2A (0.74) GRIK1MEN1KMT2AALDH1A1MAPT
SCHEMBL6431239 0.82 GRIK1 (0.77) GRIK1MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP claimed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US claimed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN claimed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP claimed
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 US claimed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS OLESEN SOEREN PETER 2011-03-24 US disclosed
US-7851492-B2 ERG channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2010-12-14 US disclosed
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP disclosed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US disclosed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN disclosed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP disclosed
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 US disclosed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias KCNJ2, KCNN3, KCNE1 GRIK1 622/4885MEN1 2084/4885KMT2A 2189/4885
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS KCNJ2, KCNN3, KCNE1 GRIK1 622/4885MEN1 2084/4885KMT2A 2189/4885
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity CPA3, HNMT, CMA1 GRIK1 655/4885MEN1 903/4885KMT2A 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.